The estimated Net Worth of Linda Palczuk is at least $101 Tisíc dollars as of 9 May 2023. Linda Palczuk owns over 2,500 units of Verrica Pharmaceuticals Inc stock worth over $101,132 and over the last 7 years Linda sold VRCA stock worth over $0.
Linda has made over 8 trades of the Verrica Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Linda bought 2,500 units of VRCA stock worth $36,900 on 9 May 2023.
The largest trade Linda's ever made was buying 10,000 units of Verrica Pharmaceuticals Inc stock on 27 May 2022 worth over $16,000. On average, Linda trades about 1,737 units every 94 days since 2017. As of 9 May 2023 Linda still owns at least 52,400 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Linda Palczuk stock trades at the bottom of the page.
Linda's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning a John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include: